| 3 Dental Supplies Stocks Likely to Gain From US-China Trade Deal |
Here we discuss three stocks from the Dental Supplies industry that are likely to earn wealth for investors. These are CAH, LH and ALGN. |
zacks.com |
2025-05-13 12:20:38 |
Czytaj oryginał (ang.) |
| 63 Top Dividend Growth Stocks For May 2025 |
I present 63 high-quality dividend growth stocks for investment for May 2025, categorized by yield: High (4%+), Medium (2.5-3.9%), and Low ( |
seekingalpha.com |
2025-05-08 15:00:00 |
Czytaj oryginał (ang.) |
| Cardinal Health releases new report on the cell and gene therapy industry |
Analysis charts the emergence and future of advanced therapies DUBLIN, Ohio , May 7, 2025 /PRNewswire/ -- Today, Cardinal Health (NYSE: CAH) released its 2025 Advanced Therapies Report: Revolutionizing patient care – the promise and potential of cell and gene therapies, providing insights into the evolving landscape of cell and gene therapies (CGTs). This inaugural report is based on a comprehensive survey of more than 100 healthcare providers as well as interviews with subject matter experts and a patient who received CAR T-cell therapy, all of whom provide valuable insights into the state of the CGT industry. |
prnewswire.com |
2025-05-07 11:30:00 |
Czytaj oryginał (ang.) |
| Cardinal Health Board of Directors Approves Quarterly Dividend |
DUBLIN, Ohio , May 5, 2025 /PRNewswire/ -- Cardinal Health (NYSE: CAH) announced today that its Board of Directors approved an increase to its quarterly dividend, to $0.5107 per share, out of the Company's capital surplus. The dividend will be payable on July 15, 2025, to shareholders of record at the close of business on July 1, 2025. |
prnewswire.com |
2025-05-05 21:30:00 |
Czytaj oryginał (ang.) |
| Are Investors Undervaluing Cardinal Health (CAH) Right Now? |
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks. |
zacks.com |
2025-05-05 14:46:06 |
Czytaj oryginał (ang.) |
| Cardinal Health, Northrop Grumman Among 7 Companies To Announce Dividend Increases In First Half Of May |
This is my latest article where I provide predictions of upcoming dividend increases from companies with long-term dividend growth histories. Industrial engineering company Parker-Hannifin announced its latest payout boost, becoming one of less than a handful of companies with a 70-year dividend growth streak. Investors can expect modest increases from several companies in the first half of May, including a 10% increase from defense company Northrop Grumman. |
seekingalpha.com |
2025-05-05 00:30:37 |
Czytaj oryginał (ang.) |
| Why Cardinal Health (CAH) is a Top Value Stock for the Long-Term |
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores. |
zacks.com |
2025-05-02 14:46:11 |
Czytaj oryginał (ang.) |
| Burn Care Market worth $3.35 billion by 2030 with 5.6% CAGR | MarketsandMarkets™ |
DELRAY BEACH, Fla., May 2, 2025 /PRNewswire/ -- The global Burn Care Market, valued at US$2.46 billion in 2024, is forecasted to grow at a robust CAGR of 5.6%, reaching US$2.55 billion in 2025 and an impressive US$3.35 billion by 2030. This market is experiencing consistent growth due to several key factors. The number of burn injuries is rising due to factors such as industrial accidents, domestic fires, and other hazards. Furthermore, advancements in treatment technologies and increased awareness and education about burn care contribute to this trend. Additionally, supportive government initiatives play a significant role in market development. The demand for effective burn treatments is rising as the global population ages. Older individuals are more susceptible to slow-healing wounds and burn complications, which, in turn, increases the need for advanced burn care products. Moreover, technological advancements in burn treatment—including innovative burn dressings, biologics, and advanced burn wound assessment devices—enhance treatment efficiency and effectiveness. Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=247121470 Browse in-depth TOC on "Burn Care Market" 345 - Tables 45 - Figures 302 - Pages By Based on products, the burn care market is categorized into five segments: advanced burn dressings, burn wound therapy devices, biologics, traditional burn care products, and other burn care products. Among these, the biologics segment is expected to register the highest CAGR during the forecast period. This growth is driven by the rising demand for advanced and effective treatment options for deep and complex burns. Biologics provide targeted healing, minimize long-term complications, and promote tissue regeneration, making them particularly suitable for treating severe burns. The increasing acceptance of these products among healthcare professionals and ongoing innovations in regenerative medicine are contributing to the strong and sustained growth of the biologics segment. By Based on burn degree, the burn care market is divided into first-degree burns (minor burns), second-degree burns (partial-thickness burns), and third-degree burns (full-thickness burns). Of these, the second-degree burns segment accounted for the largest market share of the burn care market in 2024. This is largely because partial-thickness burns occur more frequently. These burns tend to destroy the epidermis and dermis; as such, they require the application of advanced burn care products, which drives consistent demand in this segment. By geography, the market for burn care is divided into five main regions: North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. North America dominated the burn care market in 2024 with the largest market share. This is primarily because countries like the US and Canada have well-developed healthcare facilities, supporting widespread access to advanced burn care products and treatments. The region also experiences a high rate of burn injuries. The availability of key players and constant investment in research & development further consolidate North America's position in the burn care market. Request Sample Pages : https://www.marketsandmarkets.com/requestsampleNew.asp?id=247121470 The major players operating in this market are Smith+Nephew (UK), Mölnlycke Health Care AB (Sweden), Cardinal Health Inc. (US), Integra LifeSciences Holdings Corporation (US), ConvaTec Group Plc (UK), Coloplast Group (Denmark), Solventum Corporation (US), Essity Aktiebolag (Sweden), PAUL HARTMANN AG (Germany), and Organogenesis Holdings Inc. (US). SMITH+NEPHEW (UK) Smith+Nephew is distinguished by its advanced wound care solutions and robust research and development capabilities, enabling it to provide effective burn care products. Mölnlycke Health Care AB has solidified its market position through strategic partnerships. Cardinal Health Inc. utilizes its extensive distribution network and diverse product line to reach a wide range of healthcare facilities, thereby increasing its share in the burn care market. Integra LifeSciences Holdings Corporation is recognized for its broad range of biologics that offer crucial support for severe burns. ConvaTec Group Plc has strengthened its market presence through global expansion and strategic acquisitions. MOLNLYCKE HEALTH CARE AB (SWEDEN): Mölnlycke Health Care AB also boasts a comprehensive product portfolio in the advanced wound care market. The company's leading position in this sector is largely due to its robust global sales and distribution network, which allows it to effectively market its products in various countries. Mölnlycke primarily utilizes inorganic strategies, such as partnerships, to maintain its market position. For example, in May 2024, the company formed a new partnership with the Phoenix Society, a burn survivor organization in the US. Through this collaboration, Mölnlycke will support the Phoenix Society's initiatives with its extensive range of burn care solutions For more information, Inquire Now! Related Reports: Wound Care Biologics Market Advanced Wound Care Market Point of Care Diagnostics Market Wound Care Market Point of Care Molecular Diagnostics Market Get access to the latest updates on Burn Care Companies and Burn Care Market Size About MarketsandMarkets™ MarketsandMarkets™ has been recognized as one of America's Best Management Consulting Firms by Forbes, as per their recent report. MarketsandMarkets™ is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. With the widest lens on emerging technologies, we are proficient in co-creating supernormal growth for clients across the globe. Today, 80% of Fortune 2000 companies rely on MarketsandMarkets, and 90 of the top 100 companies in each sector trust us to accelerate their revenue growth. With a global clientele of over 13,000 organizations, we help businesses thrive in a disruptive ecosystem. The B2B economy is witnessing the emergence of $25 trillion in new revenue streams that are replacing existing ones within this decade. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines – TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing. Built on the 'GIVE Growth' principle, we collaborate with several Forbes Global 2000 B2B companies to keep them future-ready. Our insights and strategies are powered by industry experts, cutting-edge AI, and our Market Intelligence Cloud, KnowledgeStore™, which integrates research and provides ecosystem-wide visibility into revenue shifts. To find out more, visit www.MarketsandMarkets™.com or follow us on Twitter , LinkedIn and Facebook . Contact:Mr. Rohan SalgarkarMarketsandMarkets™ INC.1615 South Congress Ave.Suite 103, Delray Beach, FL 33445USA: +1-888-600-6441Email: [email protected]Visit Our Website: https://www.marketsandmarkets.com/ Logo: https://mma.prnewswire.com/media/1868219/MarketsandMarkets_Logo.jpg |
https://www.prnewswire.com |
2025-05-02 14:15:00 |
Czytaj oryginał (ang.) |
| Cardinal Health Lifts FY25 EPS Outlook, Sees Growth Despite Tariff Risks |
Cardinal Health Inc. CAH on Thursday reported third-quarter 2025 adjusted EPS of $2.35, up 13% year over year, beating the consensus of $2.17. |
benzinga.com |
2025-05-02 04:39:02 |
Czytaj oryginał (ang.) |
| Cardinal Health, Inc. (CAH) Q3 2025 Earnings Call Transcript |
Cardinal Health, Inc. (NYSE:CAH ) Q3 2025 Earnings Conference Call May 1, 2025 8:30 AM ET Company Participants Matt Sims - Vice President, Investor Relations Jason Hollar - Chief Executive Officer Aaron Alt - Chief Financial Officer Conference Call Participants Lisa Gill - JPMorgan Allen Lutz - Bank of America Joanna Dynak - Evercore Eric Percher - Nephron Michael Cherny - Leerink Partners Kevin Caliendo - UBS George Hill - Deutsche Bank Eric Coldwell - Baird Erin Wright - Morgan Stanley Daniel Grosslight - Citi Charles Rhyee - TD Cowen Steve Baxter - Wells Fargo Brian Tanquilut - Jefferies Steven Valiquette - Mizuho Operator Hello, and welcome to the Third Quarter Fiscal Year 2025 Cardinal Health Incorporated Earnings Conference Call. My name is George, and I'll be the coordinator for today's event. |
seekingalpha.com |
2025-05-01 15:48:45 |
Czytaj oryginał (ang.) |
| CAH Q3 Earnings Beat Estimates, '25 EPS View Raised, Stock Gains |
Cardinal Health's third-quarter fiscal 2025 results benefit from solid Medical and Other segment revenue growth. However, OptumRx contract expiry hurts Pharmaceutical segment sales. |
zacks.com |
2025-05-01 15:40:37 |
Czytaj oryginał (ang.) |
| Cardinal (CAH) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates |
Although the revenue and EPS for Cardinal (CAH) give a sense of how its business performed in the quarter ended March 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers. |
zacks.com |
2025-05-01 14:36:26 |
Czytaj oryginał (ang.) |
| Cardinal Health (CAH) Beats Q3 Earnings Estimates |
Cardinal Health (CAH) came out with quarterly earnings of $2.35 per share, beating the Zacks Consensus Estimate of $2.15 per share. This compares to earnings of $2.08 per share a year ago. |
zacks.com |
2025-05-01 12:55:39 |
Czytaj oryginał (ang.) |
| Cardinal Health lifts full-year profit forecast again on specialty medicine sales |
Drug distributor Cardinal Health on Thursday raised its fiscal 2025 adjusted profit forecast for the fourth time, betting on strong demand for costly specialty medicines and branded drugs. |
reuters.com |
2025-05-01 12:21:19 |
Czytaj oryginał (ang.) |
| Cardinal Health Reports Third Quarter Fiscal Year 2025 Results and Raises Fiscal Year 2025 Outlook |
Revenue was flat at $54.9 billion; revenue increased 19% excluding the impact of the previously communicated customer contract expiration GAAP 1 operating earnings were $730 million; GAAP diluted EPS was $2.10 Non-GAAP operating earnings increased 21% to $807 million, driven by segment profit growth across all of the company's operating segments; non-GAAP diluted EPS increased 13% to $2.35 Fiscal year 2025 non-GAAP EPS guidance2 raised and narrowed to $8.05 to $8.15, from $7.85 to $8.00 GI Alliance announces expansion into urology specialty therapeutic area DUBLIN, Ohio , May 1, 2025 /PRNewswire/ -- Cardinal Health (NYSE: CAH) today reported third quarter fiscal year 2025 revenues of $54.9 billion, flat to the third quarter of fiscal year 2024. Third quarter revenue increased 19% excluding the impact of the previously communicated customer contract expiration. |
prnewswire.com |
2025-05-01 10:45:00 |
Czytaj oryginał (ang.) |
| MedTech Stocks' Earnings to Watch on May 1: BDX, CAH, BAX, DXCM & SYK |
This earnings season so far has reflected a continued recovery in sales for companies within the Medical sector. Earnings have increased year over year, albeit at a slower pace than revenues. |
zacks.com |
2025-04-30 15:55:39 |
Czytaj oryginał (ang.) |
| Best Dividend Aristocrats For May 2025 |
Despite a strong start, the Dividend Aristocrats are underperforming the S&P 500 in April, with NOBL down 4.88% and SPY down 1.53%. The best-performing Dividend Aristocrats YTD include Consolidated Edison (+25.65%), Cardinal Health (+17.82%), and Coca-Cola (+16.18%). 33 out of 69 Dividend Aristocrats have announced dividend increases in 2025, with an average growth rate of 4.33%. |
seekingalpha.com |
2025-04-30 00:07:22 |
Czytaj oryginał (ang.) |
| Can Sustained Product Demand Drive CAH Stock Before Q3 Earnings? |
The continued solid uptake of Cardinal Health's products is expected to have driven fiscal third-quarter revenues despite an uncertain macroeconomic environment. |
zacks.com |
2025-04-29 18:10:42 |
Czytaj oryginał (ang.) |
| Cardinal (CAH) Q3 Earnings Preview: What You Should Know Beyond the Headline Estimates |
Evaluate the expected performance of Cardinal (CAH) for the quarter ended March 2025, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight. |
zacks.com |
2025-04-28 14:21:46 |
Czytaj oryginał (ang.) |
| Cardinal Health (CAH) Reports Next Week: Wall Street Expects Earnings Growth |
Cardinal (CAH) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations. |
zacks.com |
2025-04-24 15:07:18 |
Czytaj oryginał (ang.) |
| Watch These 3 Stocks for Solid Earnings Acceleration |
Prairie Operating, Intuit and Cardinal Health are exhibiting strong earnings acceleration. |
zacks.com |
2025-02-26 18:05:24 |
Czytaj oryginał (ang.) |
| Are Investors Undervaluing Cardinal Health (CAH) Right Now? |
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks. |
zacks.com |
2025-02-21 12:45:37 |
Czytaj oryginał (ang.) |
| 5 Broker-Loved Stocks to Keep an Eye on After Recent Analyst Upgrades |
Investors should monitor stocks like Dana, Camping World, ABM, Cardinal Health and DXC for high returns. |
zacks.com |
2025-02-18 10:36:07 |
Czytaj oryginał (ang.) |
| Should Value Investors Buy Cardinal Health (CAH) Stock? |
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks. |
zacks.com |
2025-02-05 12:45:46 |
Czytaj oryginał (ang.) |
| Cardinal Health Analysts Raise Their Forecasts Following Upbeat Earnings |
Cardinal Health CAH reported better-than-expected second-quarter financial results on Thursday. |
benzinga.com |
2025-02-04 15:34:21 |
Czytaj oryginał (ang.) |
| Cardinal Health Board of Directors Approves Quarterly Dividend |
DUBLIN, Ohio , Feb. 3, 2025 /PRNewswire/ -- Cardinal Health (NYSE: CAH) announced today that its Board of Directors approved a quarterly dividend of $0.5056 per share out of the Company's capital surplus. The dividend will be payable on April 15, 2025, to shareholders of record at the close of business on April 1, 2025. |
prnewswire.com |
2025-02-03 19:15:00 |
Czytaj oryginał (ang.) |
| Cardinal Health, Inc. (CAH) Q2 2025 Earnings Call Transcript |
Cardinal Health, Inc. (NYSE:CAH ) Q2 2025 Earnings Conference Call January 30, 2025 8:30 AM ET Company Participants Matt Sims - Vice President, Investor Relations Jason Hollar - Chief Executive Officer Aaron Alt - Chief Financial Officer Conference Call Participants John Stansel - JPMorgan Erin Wright - Morgan Stanley Allen Lutz - Bank of America Elizabeth Anderson - Evercore Michael Cherny - Leerink Partners Eric Percher - Nephron Kevin Caliendo - UBS Eric Coldwell - Baird Daniel Grosslight - Citi Steven Valiquette - Mizuho Charles Rhyee - TD Cowen Brian Tanquilut - Jefferies Operator Hello, and welcome to the Second Quarter Fiscal Year 2025 Cardinal Health Inc. Earnings Conference Call. My name is George, and I'll be coordinator for today's event. |
seekingalpha.com |
2025-01-30 15:32:00 |
Czytaj oryginał (ang.) |
| CAH Q2 Earnings and Sales Beat Estimates, 2025 EPS View Raised |
Cardinal Health's second-quarter fiscal 2025 results benefit from solid Other segment revenue growth. However, OptumRx contract expiry hurts Pharmaceutical segment sales. |
zacks.com |
2025-01-30 14:11:08 |
Czytaj oryginał (ang.) |
| Here's Why Cardinal Health (CAH) is a Strong Value Stock |
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage. |
zacks.com |
2025-01-30 12:46:34 |
Czytaj oryginał (ang.) |
| Cardinal (CAH) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates |
Although the revenue and EPS for Cardinal (CAH) give a sense of how its business performed in the quarter ended December 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers. |
zacks.com |
2025-01-30 12:36:07 |
Czytaj oryginał (ang.) |
| Wall Street Analysts Think Cardinal (CAH) Is a Good Investment: Is It? |
Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm employed (or sell-side) analysts often affect a stock's price, do they really matter? |
zacks.com |
2025-01-30 12:31:15 |
Czytaj oryginał (ang.) |
| Cardinal Health (CAH) Surpasses Q2 Earnings and Revenue Estimates |
Cardinal Health (CAH) came out with quarterly earnings of $1.93 per share, beating the Zacks Consensus Estimate of $1.75 per share. This compares to earnings of $1.82 per share a year ago. |
zacks.com |
2025-01-30 10:55:23 |
Czytaj oryginał (ang.) |
| Cardinal Health lifts 2025 profit forecast on specialty drugs demand |
Drug distributor Cardinal Health on Thursday raised its fiscal 2025 adjusted profit forecast as strong demand for costly specialty medicines and branded drugs drove sales at its pharmaceuticals unit. |
reuters.com |
2025-01-30 09:46:17 |
Czytaj oryginał (ang.) |
| Cardinal Health Reports Second Quarter Fiscal Year 2025 Results and Raises Fiscal Year 2025 Outlook |
Revenue decreased 4% to $55.3 billion; revenue increased 16% excluding the impact of the previously communicated large customer contract expiration GAAP 1 operating earnings were $549 million; GAAP diluted EPS was $1.65 Non-GAAP operating earnings increased 9% to $635 million, driven by the Pharmaceutical and Specialty Solutions segment; non-GAAP diluted EPS increased 2% to $1.93 Fiscal year 2025 non-GAAP EPS guidance2 raised to $7.85 to $8.00, from $7.75 to $7.90 Company announces the completion of its acquisition of 73% ownership of GI Alliance DUBLIN, Ohio , Jan. 30, 2025 /PRNewswire/ -- Cardinal Health (NYSE: CAH) today reported second quarter fiscal year 2025 revenues of $55.3 billion, a decrease of 4% from the second quarter of fiscal year 2024. Second quarter revenue increased 16% excluding the impact of the previously communicated large customer contract expiration. |
prnewswire.com |
2025-01-30 08:45:00 |
Czytaj oryginał (ang.) |
| Why Cardinal Health (CAH) is a Top Momentum Stock for the Long-Term |
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service. |
zacks.com |
2025-01-29 12:55:32 |
Czytaj oryginał (ang.) |
| Buy These 5 Stocks Set to Win Big After Earnings Results This Week |
We have narrowed our search to five corporate behemoths set to report earnings results this week. These are: CAH, LOGI, NOW, GLW, ADP. |
zacks.com |
2025-01-28 09:41:09 |
Czytaj oryginał (ang.) |
| Cardinal Health to Report Q2 Earnings: What's in Store for the Stock? |
Despite recent supply-chain challenges, new facilities and growth in branded and specialty pharmaceutical sales are likely to have driven CAH's performance in the fiscal second quarter. |
zacks.com |
2025-01-27 14:51:23 |
Czytaj oryginał (ang.) |
| Cardinal Health (CAH) Expected to Beat Earnings Estimates: Can the Stock Move Higher? |
Cardinal (CAH) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations. |
zacks.com |
2025-01-23 13:07:02 |
Czytaj oryginał (ang.) |
| Are Medical Stocks Lagging Cardinal Health (CAH) This Year? |
Here is how Cardinal Health (CAH) and AIM ImmunoTech Inc. (AIM) have performed compared to their sector so far this year. |
zacks.com |
2025-01-22 12:41:16 |
Czytaj oryginał (ang.) |
| Are Investors Undervaluing Cardinal Health (CAH) Right Now? |
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks. |
zacks.com |
2025-01-20 12:45:19 |
Czytaj oryginał (ang.) |
| Reasons to Add Cardinal Health Stock to Your Portfolio Now |
CAH continues to grow on the back of its robust product portfolio and a strong quarterly result. |
zacks.com |
2025-01-03 12:46:44 |
Czytaj oryginał (ang.) |
| Is Cardinal Health (CAH) Stock Undervalued Right Now? |
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks. |
zacks.com |
2025-01-02 12:40:24 |
Czytaj oryginał (ang.) |
| Canada Personal Protective Equipment Market Outlook to 2033 Featuring Cardinal Health, Medline Industries, and 3M |
Dublin, Dec. 30, 2024 (GLOBE NEWSWIRE) -- The "Canada Personal Protective Equipment Market Outlook to 2033 - Gloves, Gowns, Masks, Shoe Covers and Others" report has been added to ResearchAndMarkets.com's offering. The "Canada Personal Protective Equipment Market Outlook to 2033" is a comprehensive databook report, covering key market data on the Canada Personal Protective Equipment market. The databook report provides value (USD), volume (units) and average prices (USD) within market segments - Examination Table Papers, Face Shields, Gloves, Gowns, Masks, and Shoe Covers The Canada Personal Protective Equipment Market report provides key information and data on: |
globenewswire.com |
2024-12-30 06:13:00 |
Czytaj oryginał (ang.) |
| Here's Why Cardinal Health (CAH) is a Strong Value Stock |
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage. |
zacks.com |
2024-12-27 12:41:23 |
Czytaj oryginał (ang.) |
| Cardinal Health (CAH) Rises Yet Lags Behind Market: Some Facts Worth Knowing |
Cardinal Health (CAH) reachead $118.83 at the closing of the latest trading day, reflecting a +0.41% change compared to its last close. |
zacks.com |
2024-12-24 21:00:43 |
Czytaj oryginał (ang.) |
| 4 Large Cap MedTech Stocks to Keep Winning Streaks Alive in 2025 |
Investing in large-cap MedTech stocks like MCK, PEN, CAH and PEN can be profitable for investors in 2025. |
zacks.com |
2024-12-20 12:26:08 |
Czytaj oryginał (ang.) |
| Cardinal Health to Announce Second-Quarter Results for Fiscal Year 2025 on January 30 |
DUBLIN, Ohio , Dec. 19, 2024 /PRNewswire/ -- Cardinal Health (NYSE: CAH) plans to release second-quarter financial results for its fiscal year 2025 on January 30, prior to the opening of trading on the New York Stock Exchange. The company will webcast a discussion of these results beginning at 8:30 a.m. |
prnewswire.com |
2024-12-19 08:45:00 |
Czytaj oryginał (ang.) |
| Is Cardinal Health (CAH) a Great Value Stock Right Now? |
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks. |
zacks.com |
2024-12-16 18:36:12 |
Czytaj oryginał (ang.) |
| 5 Stocks With Upgraded Broker Ratings to Buy for Solid Returns in 2025 |
Brokers have deeper insights into stocks and the macroeconomic backdrop. One must follow broker rating upgrades to pick stocks like GAP, CAH, AIT, JLL and UAL. |
zacks.com |
2024-12-16 11:05:22 |
Czytaj oryginał (ang.) |
| Want Decades of Passive Income? 3 Stocks to Buy Now and Hold Forever |
Investing in a company to hold it forever is a simple idea, but it's not easy. Most companies can't maintain competitive advantages forever. |
fool.com |
2024-12-15 07:35:00 |
Czytaj oryginał (ang.) |
| Zacks Industry Outlook Becton, Dickinson, BD, McKesson, Cardinal Health and Merit Medical Systems |
Becton, Dickinson, BD, McKesson, Cardinal Health and Merit Medical Systems have been highlighted in this Industry Outlook article. |
zacks.com |
2024-12-13 05:15:24 |
Czytaj oryginał (ang.) |
| 4 Stocks to Watch Amid Dental Supplies Industry Challenges |
Here we discuss four stocks from the Dental Supplies industry that are likely to earn wealth for investors. These are BDX, MCK, CAH and MMSI. |
zacks.com |
2024-12-12 11:46:09 |
Czytaj oryginał (ang.) |
| Spruce Biosciences Announces Topline Results from CAHmelia-204 in Adult CAH and CAHptain-205 in Adult and Pediatric CAH |
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological and endocrine disorders with significant unmet medical need, today announced topline results from its CAHmelia-204 study of tildacerfont in adult CAH and its CAHptain-205 study of tildacerfont in adult and pediatric CAH. “We are very grateful to all the patients, families, investigators, and the e. |
businesswire.com |
2024-12-10 18:01:00 |
Czytaj oryginał (ang.) |
| Why Cardinal Health (CAH) is a Top Value Stock for the Long-Term |
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage. |
zacks.com |
2024-12-10 12:41:27 |
Czytaj oryginał (ang.) |
| Strength Across Segments to Help CAH Stock Offset OptumRx Headwind? |
CAH gains from a solid pharmaceutical segment and a diversified product portfolio. However, concentrated revenue generation and regulatory setbacks are a concern. |
zacks.com |
2024-12-05 10:50:42 |
Czytaj oryginał (ang.) |
| Cardinal Health, Inc. (CAH) Annual Evercore ISI HealthCONx Healthcare Conference (Transcript) |
Cardinal Health, Inc. (NYSE:CAH ) Annual Evercore ISI HealthCONx Healthcare Conference December 3, 2024 1:30 PM ET Company Participants Matt Sims - VP, IR Aaron Alt - CFO Conference Call Participants Elizabeth Anderson - Evercore ISI Elizabeth Anderson Hi, everybody. Thanks so much for joining us today. |
seekingalpha.com |
2024-12-04 00:34:10 |
Czytaj oryginał (ang.) |
| Cardinal Health, Inc. (CAH) Citi's 2024 Global Healthcare Conference (Transcript) |
Cardinal Health, Inc. (NYSE:CAH ) Citi's 2024 Global Healthcare Conference Call December 3, 2024 8:00 AM ET Company Participants Aaron Alt - Chief Financial Officer Matt Sims - Head, Investor Relations Conference Call Participants Daniel Grosslight - Citi Daniel Grosslight Thanks for joining us for the Cardinal Health fireside chat here at Citi's Global Healthcare Conference. My name is Daniel Grosslight. |
seekingalpha.com |
2024-12-03 12:34:10 |
Czytaj oryginał (ang.) |
| Should Value Investors Buy Cardinal Health (CAH) Stock? |
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks. |
zacks.com |
2024-11-29 12:40:39 |
Czytaj oryginał (ang.) |
| CAH Stock Gains on the Launch of Kendall SmartFlow Compression System |
Cardinal Health launches the next generation of the Kendall Compression Series, Kendall SCD SmartFlow Compression System, to aid pain relating to venous stasis. |
zacks.com |
2024-11-22 14:06:10 |
Czytaj oryginał (ang.) |
| Cardinal Health launches Kendall SCD SmartFlow™ Compression System |
Next generation of the Kendall™ SCD Series delivers an all-in-one solution for deep vein thrombosis and pulmonary embolism prevention DUBLIN, Ohio , Nov. 20, 2024 /PRNewswire/ -- Cardinal Health (NYSE: CAH) announced today the U.S. launch of its Kendall SCD SmartFlow™ Compression System, the next generation of the Kendall™ Compression Series offering an enhanced clinician and patient experience. Featuring clinically proven technology that delivers customized, intermittent pneumatic compression (IPC) to increase blood flow1 in at-risk patients, the Kendall SCD SmartFlow™ System is designed to help prevent venous thromboembolism (VTE) events, as well as enhance blood circulation and treat pain and swelling related to venous stasis. |
prnewswire.com |
2024-11-20 09:30:00 |
Czytaj oryginał (ang.) |